1-Palmitoyl-d9-2-hydroxy-sn-glycero-3-PA
(Synonyms: 1-Hexadecanoyl-d9-2-hydroxy-sn-glycero-3-phosphate,16:0-d9 LPA,LPA 16:0-d9,PA(16:0-d9/0:0),1-Palmitoyl-d9 LPA,1-Palmitoyl-d9 Lysophosphatidic Acid) 目录号 : GC916201-Palmitoyl-d9-2-hydroxy-sn-glycero-3-PA (1-palmitoyl-d9 LPA) is intended for use as an internal standard for the quantification of 1-palmitoyl LPA by GC- or LC-MS.
Cas No.:2830282-77-2
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Quality Control & SDS
- View current batch:
- Purity: >99.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
1-Palmitoyl-d9-2-hydroxy-sn-glycero-3-PA (1-palmitoyl-d9 LPA) is intended for use as an internal standard for the quantification of 1-palmitoyl LPA by GC- or LC-MS. 1-Palmitoyl LPA is an analog of LPA that contains palmitic acid at the sn-1 position. It induces reporter gene expression in PC12 cells expressing human lysophosphatidic acid receptor 4 (LPA4) when used at concentrations ranging from 0.01 to 10 µM.[1] 1-Palmitoyl LPA (12-300 µM) induces aggregation of isolated human platelets, an effect that can be reversed by prostaglandin E1 (PGE1; ), theophylline , or EDTA.[2] It also binds to calcium and magnesium and enhances the activity of ampicillin , piperacillin , and ceftazidime against P. aeruginosa isolates from patients with cystic fibrosis.[3]
References:
[1].Noguchi, K., Ishii, S., and Shimizu, T.Identification of p2y9/GPR23 as a novel G protein-coupled receptor for lysophosphatidic acid, structurally distant from the Edg familyJ. Biol. Chem.278(28)25600-25606(2003).
[2].Gerrard, J.M., Kindom, S.E., Peterson, D.A., et al.Lysophosphatidic acids. Influence on platelet aggregation and intracellular calcium fluxAm. J. Pathol.96(2)423-438(1979).
[3].Krogfelt, K.A., Utley, M., Krivan, H.C., et al.Specific phospholipids enhance the activity of β-lactam antibiotics against Pseudomonas aeruginosaJ. Antimicrob. Chemother.46(3)377-384(2000).
| Cas No. | 2830282-77-2 | SDF | Download SDF |
| 别名 | 1-Hexadecanoyl-d9-2-hydroxy-sn-glycero-3-phosphate,16:0-d9 LPA,LPA 16:0-d9,PA(16:0-d9/0:0),1-Palmitoyl-d9 LPA,1-Palmitoyl-d9 Lysophosphatidic Acid | ||
| 分子式 | C19H30D9O7P | 分子量 | 419.5 |
| 溶解度 | Ethanol: 10 mg/ml | 储存条件 | -20°C |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 2.3838 mL | 11.919 mL | 23.8379 mL |
| 5 mM | 0.4768 mL | 2.3838 mL | 4.7676 mL |
| 10 mM | 0.2384 mL | 1.1919 mL | 2.3838 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。